263 related articles for article (PubMed ID: 24746204)
1. Morphologic and GATA1 sequencing analysis of hematopoiesis in fetuses with trisomy 21.
Hoeller S; Bihl MP; Tzankov A; Chaffard R; Hirschmann P; Miny P; Kühne T; Bruder E
Hum Pathol; 2014 May; 45(5):1003-9. PubMed ID: 24746204
[TBL] [Abstract][Full Text] [Related]
2. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
Satgé D
Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
[TBL] [Abstract][Full Text] [Related]
3. Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.
Vyas P; Roberts I
Early Hum Dev; 2006 Dec; 82(12):767-73. PubMed ID: 17064858
[TBL] [Abstract][Full Text] [Related]
4. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
5. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
[TBL] [Abstract][Full Text] [Related]
6. Induction of hyperproliferative fetal megakaryopoiesis by an N-terminally truncated GATA1 mutant.
Shimizu R; Kobayashi E; Engel JD; Yamamoto M
Genes Cells; 2009 Sep; 14(9):1119-31. PubMed ID: 19682090
[TBL] [Abstract][Full Text] [Related]
7. Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
Cushing T; Clericuzio CL; Wilson CS; Taub JW; Ge Y; Reichard KK; Winter SS
J Pediatr; 2006 May; 148(5):687-9. PubMed ID: 16737888
[TBL] [Abstract][Full Text] [Related]
8. Molecular insights into Down syndrome-associated leukemia.
Vyas P; Crispino JD
Curr Opin Pediatr; 2007 Feb; 19(1):9-14. PubMed ID: 17224656
[TBL] [Abstract][Full Text] [Related]
9. Trisomy 21 enhances human fetal erythro-megakaryocytic development.
Chou ST; Opalinska JB; Yao Y; Fernandes MA; Kalota A; Brooks JS; Choi JK; Gewirtz AM; Danet-Desnoyers GA; Nemiroff RL; Weiss MJ
Blood; 2008 Dec; 112(12):4503-6. PubMed ID: 18812473
[TBL] [Abstract][Full Text] [Related]
10. Severe TMD/AMKL with GATA1 mutation in a stillborn fetus with Down syndrome.
Heald B; Hilden JM; Zbuk K; Norton A; Vyas P; Theil KS; Eng C
Nat Clin Pract Oncol; 2007 Jul; 4(7):433-8. PubMed ID: 17597708
[TBL] [Abstract][Full Text] [Related]
11. [GATA1 analysis in myeloproliferative disorders associated to trisomy 21].
Fuster Soler JL; Norton A; Galera Miñarro A; Bermúdez Cortés M; Llinares Riestra ME; Ortuño Giner F
An Pediatr (Barc); 2011 Jan; 74(1):31-7. PubMed ID: 20870473
[TBL] [Abstract][Full Text] [Related]
12. The impact of trisomy 21 on early human hematopoiesis.
Roy A; Cowan G; Vyas P; Roberts I
Cell Cycle; 2013 Feb; 12(4):533-4. PubMed ID: 23343767
[No Abstract] [Full Text] [Related]
13. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
[TBL] [Abstract][Full Text] [Related]
14. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
[TBL] [Abstract][Full Text] [Related]
15. [The role of GATA1 mutation in acute megakaryocytic leukemia].
Ito E
Rinsho Ketsueki; 2006 Nov; 47(11):1415-22. PubMed ID: 17176883
[No Abstract] [Full Text] [Related]
16. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations.
Tunstall-Pedoe O; Roy A; Karadimitris A; de la Fuente J; Fisk NM; Bennett P; Norton A; Vyas P; Roberts I
Blood; 2008 Dec; 112(12):4507-11. PubMed ID: 18689547
[TBL] [Abstract][Full Text] [Related]
17. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.
Sandoval C; Pine SR; Guo Q; Sastry S; Stewart J; Kronn D; Jayabose S
Pediatr Blood Cancer; 2005 Jan; 44(1):85-91. PubMed ID: 15390279
[TBL] [Abstract][Full Text] [Related]
18. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
[TBL] [Abstract][Full Text] [Related]
19. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
[TBL] [Abstract][Full Text] [Related]
20. Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis.
Sit YT; Takasaki K; An HH; Xiao Y; Hurtz C; Gearhart PA; Zhang Z; Gadue P; French DL; Chou ST
JCI Insight; 2023 Oct; 8(23):. PubMed ID: 37906251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]